Avalo Therapeutics Inc. has released a corporate presentation highlighting their development of targeted therapies for immune-mediated inflammatory diseases. The lead compound, AVTX-009, an anti-IL-1β monoclonal antibody, is positioned as a potential "best-in-disease" therapy for hidradenitis suppurativa (HS). The company emphasizes AVTX-009's higher affinity and longer half-life compared to lutikizumab, suggesting potential for greater efficacy and more convenient dosing. The Phase 2 LOTUS trial for AVTX-009 in HS has commenced, with topline data anticipated by mid-2026. Avalo also indicates a cash runway extending into at least 2027. The HS market is projected to exceed $10 billion by 2035. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.